Adverum Biotech
Jennifer Seto is an accomplished quality assurance professional with extensive experience in document control and system administration within the biotechnology and pharmaceutical industries. Currently serving as a Senior QA Manager and MasterControl Project Administrator at Adverum Biotechnologies since March 2022, Jennifer has previously held key positions including Senior Specialist in Document Control at Rigel Pharmaceuticals and Document Control Supervisor/Training Coordinator at Myriad Genetics. Jennifer's background includes expertise in Veeva Vault and MasterControl systems, along with a strong foundation in quality management, internal audits, and regulatory compliance. Jennifer earned a Bachelor of Science degree in Biochemistry and Molecular Biology from the University of California, Davis.
Adverum Biotech
9 followers
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.